US regulator approves galantamine prodrug for Alzheimer’s
The US Food and Drug Administration (FDA) has granted approval for Alpha Cognition’s Zunveyl (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease (AD). Tolerability affects therapy adherence, with data showing that 55% of AD patients discontinue their medication after one year, mainly… Read More